Related Experiment Video

Updated: Dec 6, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

909

Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2

Shuang Dong1,2,3, Chenggang Luo2,3,4,5, Xuebo Hu6

  • 1Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Frontiers in Oncology
|October 5, 2020
PubMed

Insights

Cancer patients face increased risks from COVID-19 due to compromised immunity. This guideline offers expert consensus on managing SARS-CoV-2 in cancer care, balancing treatment risks and patient needs.

Area of Science:

  • Oncology
  • Infectious Diseases
  • Public Health

Background:

  • The COVID-19 pandemic presents a significant global health threat, particularly impacting immunocompromised individuals.
  • Cancer patients possess compromised immune systems, increasing their vulnerability to SARS-CoV-2 infection and severe outcomes.
  • Limited clinical data exists regarding the prevalence and management of COVID-19 in cancer patient populations.

Purpose of the Study:

  • To develop a clinical guideline and expert consensus for managing COVID-19 in cancer patients.
  • To address the unique challenges faced by cancer patients during the SARS-CoV-2 pandemic.
  • To provide evidence-based recommendations integrating clinical experience and existing guidelines.

Main Methods:

  • Compilation of medical references and guidelines from leading health organizations (CDC, NCI, ASCO, ESMO, NCCN, AACR, NHC China).
  • Formulation of a guideline based on clinical experience from a specialized cancer hospital in Wuhan.
  • Development of an expert consensus through multidisciplinary discussion and analysis of available COVID-19 information.

Main Results:

  • A proposed expert consensus emphasizing a multidisciplinary team diagnostic model.
  • Recommendations for assessing the risk-benefit balance before initiating cancer treatment.
  • Focus on individualizing patient care to meet medical needs while considering ethical and socio-economic factors.

Conclusions:

  • The consensus provides a framework for optimizing COVID-19 management in cancer patients.
  • A balanced, individualized, and ethically considerate approach is crucial for cancer care during the pandemic.
  • This guideline aims to support clinicians in navigating the complexities of treating cancer patients with SARS-CoV-2.
Keywords:
COVID-19SARS-Cov-2cancerconsensuscoronavirusimmunotherapytreatment

More Related Videos

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

10.1K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
557
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
852